2017
Predictive Ability of Intermittent Daily Sickle Cell Pain Assessment: The PiSCES Project
Smith WR, McClish DK, Levenson J, Aisiku I, Dahman B, Bovbjerg VE, Roseff S, Roberts J. Predictive Ability of Intermittent Daily Sickle Cell Pain Assessment: The PiSCES Project. Pain Medicine 2017, 19: 1972-1981. PMID: 29036363, PMCID: PMC6176749, DOI: 10.1093/pm/pnx214.Peer-Reviewed Original ResearchConceptsSickle cell diseasePain daysPain assessmentPain measuresOne weekGold standardSickle Cell Epidemiology StudyMonths strategyDaily pain assessmentProspective cohort studyOne dayPiSCES projectCohort studySCD patientsMeasurement of R2Month assessmentCell diseasePainEpidemiology studiesDiary assessmentsDaily assessmentIntermittent assessmentCrisis daysWeeksMonths
2016
Phase I study of pemetrexed with sorafenib in advanced solid tumors
Poklepovic A, Gordon S, Shafer DA, Roberts JD, Bose P, Geyer CE, McGuire WP, Tombes MB, Shrader E, Strickler K, Quigley M, Wan W, Kmieciak M, Massey HD, Booth L, Moran RG, Dent P. Phase I study of pemetrexed with sorafenib in advanced solid tumors. Oncotarget 2016, 7: 42625-42638. PMID: 27213589, PMCID: PMC5173162, DOI: 10.18632/oncotarget.9434.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCohort StudiesFemaleHumansInflammationMaleMaximum Tolerated DoseMiddle AgedNeoplasmsNiacinamidePemetrexedPhenylurea CompoundsPTEN PhosphohydrolaseSorafenibTreatment OutcomeTriple Negative Breast NeoplasmsConceptsAdvanced solid tumorsDay 1Solid tumorsOral sorafenibDose scheduleBreast cancerTriple-negative breast cancerDose-escalation schemaPhase II dosePhase I trialSorafenib dosingSorafenib therapyStable diseaseCohort BComplete responseI trialPartial responseTolerable combinationRadiographic assessmentCumulative toxicityCombination treatmentPatientsSorafenibPhase IAntitumor activity
2010
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors
Dickson MA, Rathkopf DE, Carvajal RD, Grant S, Roberts JD, Reid JM, Ames MM, McGovern RM, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, Schwartz GK. A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Investigational New Drugs 2010, 29: 1004-1012. PMID: 20461440, PMCID: PMC3545439, DOI: 10.1007/s10637-010-9447-x.Peer-Reviewed Original ResearchConceptsSerum levelsPhase I pharmacokinetic studyIntermittent high doseResults 34 patientsD1-3I pharmacokinetic studyCyclin-dependent kinase inhibitor flavopiridolKinase inhibitor flavopiridolStable diseaseOral doseOral dosingHigh doseCombination treatmentPatientsSolid tumorsCmaxOne weekDosePharmacokinetic studyVorinostatMTDFlavopiridolNeutropeniaChemotherapyLevels
2009
Pain site frequency and location in sickle cell disease: The PiSCES project
McClish DK, Smith WR, Dahman BA, Levenson JL, Roberts JD, Penberthy LT, Aisiku IP, Roseff SD, Bovbjerg VE. Pain site frequency and location in sickle cell disease: The PiSCES project. Pain 2009, 145: 246-251. PMID: 19631468, PMCID: PMC2771372, DOI: 10.1016/j.pain.2009.06.029.Peer-Reviewed Original ResearchConceptsPain locationPain daysPain sitesBody chartSickle Cell Disease PainFrequency of painDaily pain diarySickle cell diseasePiSCES projectPain crisisDisease painED utilizationPain diaryFrequent painHealthcare utilizationEpidemiologic descriptionTreatment optionsLower extremitiesCell diseaseUpper backPainSCD managementUnplanned utilizationSixty subjectsUnderstanding of combinations
2007
Patient satisfaction in specialized versus nonspecialized adult sickle cell care centers: the PiSCES study.
Aisiku IP, Penberthy LT, Smith WR, Bovbjerg VE, McClish DK, Levenson JL, Roberts JD, Roseff SD. Patient satisfaction in specialized versus nonspecialized adult sickle cell care centers: the PiSCES study. Journal Of The National Medical Association 2007, 99: 886-90. PMID: 17722665, PMCID: PMC2574305.Peer-Reviewed Original ResearchConceptsNonspecialized centersPatient satisfactionSpecialized centersSCD careSCD patientsCare centerInterpersonal mannerSatisfaction scoresHighest mean satisfaction scoreSickle cell disease patientsProspective cohort studyGeneral satisfactionPatient satisfaction surveyMean satisfaction scoreQuality of careHigher satisfaction scoresSatisfaction surveySCD specialistsCohort studySignificant group differencesPotential confoundersDisease patientsAmbulatory carePatientsPractice style
2006
Gender Differences in Pain and Healthcare Utilization for Adult Sickle Cell Patients: The PiSCES Project
McClish DK, Levenson JL, Penberthy LT, Roseff SD, Bovbjerg VE, Roberts JD, Aisiku IP, Smith WR. Gender Differences in Pain and Healthcare Utilization for Adult Sickle Cell Patients: The PiSCES Project. Journal Of Women's Health 2006, 15: 146-154. PMID: 16536678, DOI: 10.1089/jwh.2006.15.146.Peer-Reviewed Original ResearchConceptsHealthcare utilizationAnalysis of covarianceAdult sickle cell patientsSickle cell disease (SCD) experienceSS genotypeEpisodes of painProspective cohort studyIntensity of painSickle cell crisisSickle cell patientsHigher pain ratingsStudy of PainPiSCES projectOpioid usagePain scoresAcute painCohort studyChronic painPain ratingsLower painCell crisisCell patientsPainPain experienceDisease experience
1998
Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
Grant S, Roberts J, Poplin E, Tombes MB, Kyle B, Welch D, Carr M, Bear HD. Phase Ib trial of bryostatin 1 in patients with refractory malignancies. Clinical Cancer Research 1998, 4: 611-8. PMID: 9533528.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsBryostatinsCohort StudiesCytotoxicity, ImmunologicDrug Administration ScheduleFemaleHumansImmunophenotypingInfusions, IntravenousInterleukin-2LactonesLymphocyte ActivationLymphocytesLymphomaMacrolidesMaleMetabolic Clearance RateMiddle AgedNeoplasmsPatient SelectionPlatelet AggregationProtein Kinase CConceptsPhase Ib trialIb trialCohort 3Lymphokine-activated killer cell activityBryostatin 1Bryostatin-1 administrationObjective clinical responsesKiller cell activityLiver function testsSubset of patientsBryostatin 1 treatmentSignificant posttreatment increasePKC activitySplit courseClinical responseFirst doseLiver metastasesNonhematological malignanciesRefractory malignanciesFunction testsPatient cohortCohort 1Interleukin-2Immunophenotypic profileTransient elevation